Drug Profile
Spartalizumab - Novartis Oncology
Alternative Names: PDR 001Latest Information Update: 25 Jan 2024
Price :
$50
*
At a glance
- Originator Novartis
- Developer EUSA Pharma; Novartis; Novartis Oncology; SOLTI Breast Cancer Research Group; Yonsei University
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Anal cancer; Breast cancer; Cancer; Colorectal cancer; Diffuse large B cell lymphoma; Gastric cancer; Malignant melanoma; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
- Phase I/II Gastrointestinal stromal tumours; Liver cancer; Prostate cancer
- Phase I Renal cell carcinoma
- No development reported Acute myeloid leukaemia; Lymphoma; Multiple myeloma; Myelodysplastic syndromes; Myelofibrosis; Ovarian cancer; Renal cancer; Squamous cell cancer
- Discontinued Neuroendocrine tumours
Most Recent Events
- 27 Dec 2023 Novartis Pharmaceuticals terminates a phase I trial for Solid tumours in Belgium, Germany, Italy, Japan, Multinational, Spain, Taiwan, USA (NCT04261439)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, Second-line therapy or greater) in Australia (IV)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Combination therapy, Second-line therapy or greater) in Finland (IV)